Investor Relations
Investor Relations
Corporate Profile
Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, we are developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably, and at greater scale to more patients.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Sep 02
2020
2020
Allogene Therapeutics Announces September 2020 Virtual Investor Conference Participation
Learn More >
Aug 05
2020
2020
Allogene Therapeutics Reports Second Quarter 2020 Financial Results
Learn More >
Jul 28
2020
2020
Allogene Therapeutics to Report Second Quarter 2020 Financial Results on August 5, 2020
Learn More >
Jul 07
2020
2020
Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board
Learn More >
Jul 01
2020
2020
Allogene Therapeutics Announces Ton Schumacher, Ph.D., Chair of Scientific Advisory Board, Awarded the Dutch Research Council’s Stevin Prize
Learn More >
Jun 22
2020
2020
Allogene Therapeutics Presents Preclinical Findings Supporting an Allogeneic DLL3 CAR for Small Cell Lung Cancer and Development of an Inducible TurboCAR™ at the American Association for Cancer Research (AACR) Virtual 2020 Meeting
Learn More >
Jun 22
2020
2020
Allogene Therapeutics Announces Publication Highlighting Potential for ALLO-819 In Acute Myeloid Leukemia
Learn More >
Jun 03
2020
2020
Allogene Therapeutics Announces June 2020 Virtual Investor Conference Participation
Learn More >
Jun 01
2020
2020
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
Learn More >
Jun 01
2020
2020